Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment ...
Cancer Burden in Bangladesh: Insights From National Institute of Cancer Research & Hospital, 2014-2020 Hepatocellular carcinoma (HCC) is a major cause of cancer mortality in sub-Saharan Africa, with ...
Current opinion holds that hepatocellular carcinoma (HCC) arises as a stepwise progression from chronic liver disease (CLD) to cirrhosis and then to HCC. However, some HCCs may develop in a ...
An interview with Dr. John D. Gordan from the University of California, San Francisco, and Dr. Michal G. Rose from Yale Cancer Center and VA Connecticut Healthcare System on "Systemic Therapy for ...
The incidence of hepatocellular carcinoma (HCC) in non-cirrhotic livers is rising significantly, but clear risk factors for screening remain elusive. This study sought to characterize non-cirrhotic ...
Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver ...
The guidelines include recommendations for first-, second-, and third-line therapy. The American Society of Clinical Oncology (ASCO) has updated its guidelines on the use of systemic therapy for ...
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver ...
Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...
The National Cancer Center (NCC), led by President Yang Han-gwang, jointly announced the revised 2026 hepatocellular carcinoma (HCC) clinical guidelines with th ...
Introduction Risk Factors and High-Risk Populations Screening Tools Screening Recommendations References A cost-effectiveness model shows a ≥ 3-month gain in life expectancy at a cost of < $50,000 per ...
Enhanced, abbreviated MRI (AMRI) outperformed ultrasonography (US) as a screen for early liver cancer in high-risk patients with cirrhosis, according to a single-center, randomized clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results